Contents

Bangavax

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.^{[1][2][3][4][5][6]} The vaccine was initially called Bancovid.^[7] On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial.^[8][9]

On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a COVID-19 vaccine under development.^[1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies.^[10] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax.^[7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax.^[4] The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation.^[11]

Globe Biotech published full research data in Vaccine journal in May 2021.^[12]

After five months of delays Bangladesh Medical Research Council conditionally grants ethical permission. Before proceeding to human trials, they have to apply the vaccine on monkeys or chimpanzees before proceeding to human trials. According to Md Harunur Rashid, chairman of Globe Biotech, "There are two types of mRNA vaccines: pure and modified. The modified one requires trials on monkeys. As Globe is making the pure mRNA one, trials on monkeys are unnecessary. Furthermore, there are no third-party CROs in the country that could conduct monkey trials. Regardless of the drawbacks, Globe will fulfil all the conditions that the government requires it to."^[13]

As of February 2022, human clinical trials are underway and are expected to continue for at least six months.^[14]

Scholia has a profile for Bangavax (Q106809739).

Viruses

COVID-19

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it.